Title: Increases in seroconversion among patients undergoing immunotherapy after a third COVID-19 vaccine dose: Variable A: Anti-CD20 therapy; 36.8% to 45.6% Variable B: S1P modulators; 35.5% to 48.4% Variable C: Mycophenolate mofetil combination treatments; 52.5% to 89.5%